Market Overview

The global pet cancer therapeutics market size was valued at USD 320.2 Million in 2024 and is projected to reach USD 664.8 Million by 2033. The market is expected to grow at a CAGR of 8.03% during the forecast period of 2025-2033. Growth is driven by rising pet ownership, advancements in veterinary medicine, enhanced research, and increased awareness of pet cancer therapeutics benefits.

Study Assumption Years

• Base Year: 2024
• Historical Year/Period: 2019-2024
• Forecast Year/Period: 2025-2033

Pet Cancer Therapeutics Market Key Takeaways

• The global pet cancer therapeutics market size was USD 320.2 Million in 2024.
• The market is forecasted to reach USD 664.8 Million by 2033.
• The market is expected to grow at a CAGR of 8.03% during 2025-2033.
• Increasing pet ownership rates and strengthening human-animal bond drive demand.
• Advancements in veterinary oncology and targeted therapies are expanding treatment options.
• Growing veterinary healthcare expenditure supports market expansion.
• North America currently dominates the market due to advanced veterinary infrastructure and high pet ownership.

Sample Request Link: https://www.imarcgroup.com/pet-cancer-therapeutics-market/requestsample

Market Growth Factors

Pet ownership grows and the human-animal bond closes for the growth of the pet cancer therapeutics market. To an increasing extent, pets are seen as part of the family, with consumers willing to pay for newer therapies. Market growth will progress through 2030 because demand exists for treatments. These treatments will help improve the quality of life and longevity of pets.

Veterinary oncology advanced. Earlier cancer diagnosis became possible so earlier intervention followed. Veterinary oncology's continuing research and technological advances show the promise of genetically targeted therapies, immunotherapies, and novel therapies that may be tailored to an individual patient, suggesting that cancer may become a treatable disease in pet animals using these technologies.

As a society, the pet is viewed as a valued family member, resulting in an increased expenditure by an owner to provide effective therapy (including cancer therapeutics) to improve their pet's outlook. This increase in cost enables greater research efforts to develop new, advanced therapies for the treatment of cancers in dogs and cats.

Market Segmentation

Breakup by Therapy:

• Chemotherapy: Chemotherapy dominates the market as the largest segment. It is widely used as a standard treatment targeting rapidly dividing cancer cells, treating diverse pet cancers like lymphoma, mast cell tumors, and osteosarcoma. Advances have made it more targeted and less toxic, improving pets' quality of life.
• Radiation Therapy
• Immunotherapy
• Combination Therapy
• Others

Breakup by Animal Species:

• Dogs: Dogs hold the largest share due to their higher vulnerability to cancers similar to humans. Common cancers include lymphoma, melanoma, and mammary tumors. Veterinary oncology research on dogs has advanced targeted and immunotherapies benefiting both pets and humans.
• Cats
• Others

Breakup by Cancer Type:

• Mast Cell Cancer: Mast cell cancer is the most prevalent type, especially common in dogs as a skin cancer affecting various breeds. Its diverse behavior requires specialized therapeutics. Ongoing research focuses on targeted and immunotherapies for effective management.
• Lymphoma
• Melanoma
• Mammary and Squamous Cell Cancer
• Others

Breakup by End User:

• Veterinary Hospitals and Clinical Pharmacies: This segment accounts for the largest market share. These institutions serve as key distribution and treatment centers, providing access to chemotherapy agents, targeted therapies, and immunotherapies. Their expertise improves treatment outcomes and pet owner confidence.
• Retail Pharmacies
• Online Pharmacies
• Others

Regional Insights

North America exhibits clear dominance in the pet cancer therapeutics market. The region benefits from high pet ownership rates, a strong human-animal bond, and advanced veterinary healthcare infrastructure. It leads in veterinary medicine innovations and oncology research, supported by collaborations among veterinary hospitals, research institutions, and pharmaceutical companies. These factors collectively drive market growth in North America.

Recent Developments & News

In July 2023, Boehringer Ingelheim International GmbH received U.S. FDA approval for NexGard PLUS, a chewable tablet protecting dogs from internal and external parasites with active ingredients afoxolaner, moxidectin, and pyrantel. In December 2022, Elanco Animal Health Incorporated secured FDA approval for Bexacat (bexagliflozin tablets), the first oral treatment for feline diabetes. In November 2021, ELIAS Animal Health LLC obtained exclusive in-license for an Oncolytic Vaccinia Virus Treatment targeting pet cancers, utilizing a modified virus to directly attack cancer cells.

Key Players

• AB Science
• Boehringer Ingelheim International GmbH
• Elanco Animal Health Incorporated
• ELIAS Animal Health LLC
• Karyopharm Therapeutics
• Pfizer Inc.
• Regeneus Ltd.
• Rhizen Pharmaceuticals AG
• Torigen Pharmaceuticals Inc.
• VetDC Inc.
• Virbac
• Zoetis Inc.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Request For Customization: https://www.imarcgroup.com/request?type=report&id=4472&flag=E

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302